Research
Molecular
Resmetirom has shown positive effects regarding CVD risk in the context of MASLD treatment.
Consider resmetirom as a potential treatment option for patients with MASLD at risk for CVD.
StrongSupportsmedium confidence
Recently, a novel drug for metabolic dysfunction-associated steatohepatitis (MASH), resmetirom, has shown positive effects regarding CVD risk.
Why this rating
Based on the review of resmetirom's effects.
Source
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
Marios Zisis et al. · Biomolecules · 2025
reviewCited 30×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →